notification of additional charge for regulation of asu and h drugs at central level against the newly created nine regulatory post

## Policy Analysis Report: Ministry of Ayush Notification S.O. 4562(E) **1. Executive Summary:** This report analyzes Notification S.O. 4562(E) issued by the Ministry of Ayush on September 27, 2022, which outlines the appointment of officers within the Ministry to the additional charge of Drug Controllers and Drug Inspectors for Ayurveda, Siddha, Unani, and Homoeopathic drugs. This notification is likely an amendment/replacement of a previous notification (G.S.R 323E, dated the 22nd March, 2018) and aims to streamline the regulatory oversight of these drug categories by assigning specific officers to these roles. The key finding is the delegation of additional responsibilities related to drug regulation to existing research officers and advisors within the Ministry. **2. Introduction:** This report provides an overview and analysis of Notification S.O. 4562(E) issued by the Ministry of Ayush on September 27, 2022, based solely on the information contained within the provided policy text. This analysis aims to inform stakeholders about the policy's objectives, provisions, and potential implications. **3. Policy Overview:** * This notification supersedes the previous notification G.S.R 323E, dated the 22nd March, 2018. * **Core Objective:** The primary objective is to assign specific officers within the Ministry of Ayush to the additional charge of Drug Controllers and Drug Inspectors for Ayurveda, Siddha, Unani, and Homoeopathic drugs across India, as per the Drugs and Cosmetics Rules, 1945. **4. Background and Rationale:** The notification appears to be a measure to enhance or adjust the regulatory framework for Ayurveda, Siddha, Unani, and Homoeopathic drugs. The reason for superseding the 2018 notification is not explicitly stated but can be inferred that the ministry is intending to update the officers who are assigned to these drug control responsibilities. The amendment likely aims to improve the efficiency and effectiveness of drug regulation by assigning specific individuals to oversight roles. **5. Key Provisions / Changes:** This notification outlines the appointment of specific officers to new roles and supersedes a previous notification. The key change is the assignment of additional responsibilities. * **Specific Part of Original Policy Changed:** This notification supersedes the earlier notification of the Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy, published in the Gazette of India, Extraordinary vide number G.S.R 323E, dated the 22nd March, 2018, * **New Rule/Provision:** * Dr. Suresh Kumar, Deputy Advisor Ayurveda, Ministry of Ayush, is assigned the additional charge of Deputy Drug Controller Ayurveda, Siddha, Unani, and Homoeopathy. * Dr. Rachna Paliwal, Assistant Adviser Homoeopathy, Ministry of Ayush, is assigned the additional charge of Assistant Drug Controller Homoeopathy. * Drs. D. Kumaran, Aswani G.S., Heena Ashokbhai Maheshwari, Hemlata Soni, Sonalben Kantilal Chaudhari, Nirma Bansal, and Asma Abid, all Research Officers in their respective fields (Siddha, Ayurveda, Unani), are assigned the additional charge of Drug Inspector for their respective field. * **Difference/Effect:** The effect of this change is to formally designate specific individuals within the Ministry of Ayush with the responsibility and authority to oversee and enforce regulations related to Ayurveda, Siddha, Unani, and Homoeopathic drugs. This likely aims to strengthen the regulatory oversight of these drug categories. It also stipulates that these additional duties will be performed without any additional remuneration. **6. Target Audience and Stakeholders:** The primary target audience includes: * Officers of the Ministry of Ayush listed in the table. * Manufacturers and distributors of Ayurveda, Siddha, Unani, and Homoeopathic drugs. * Consumers of Ayurveda, Siddha, Unani, and Homoeopathic drugs. * The regulatory bodies involved in drug control in India. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Ministry of Ayush is the primary responsible agency. * **Timelines/Procedures:** The notification is effective from the date of its publication (September 27, 2022). The specific procedures for the officers to assume their additional charges are not detailed in the text but would likely follow standard administrative protocols. * **Implementation of Changes:** The designated officers are expected to immediately commence discharging their additional duties related to drug control and inspection. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of these changes are: * Enhanced regulatory oversight of Ayurveda, Siddha, Unani, and Homoeopathic drugs. * Improved enforcement of the Drugs and Cosmetics Rules, 1945, pertaining to these drug categories. * Potentially increased compliance among manufacturers and distributors. * Improved quality and safety of Ayurveda, Siddha, Unani, and Homoeopathic drugs available in the market. **9. Conclusion:** Notification S.O. 4562(E) represents a targeted effort by the Ministry of Ayush to strengthen the regulatory oversight of Ayurveda, Siddha, Unani, and Homoeopathic drugs by assigning additional responsibilities to existing officers within the Ministry. This adjustment to the regulatory structure aims to improve the efficiency and effectiveness of drug control, ultimately contributing to the quality and safety of these traditional medicine systems. This demonstrates the ministry's commitment to regulating this industry.

Key Entities Referenced